Once completed, our new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton will be our first manufacturing facility in Texas. The site is expected to become fully operational in 2028.
RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue.
Key Facts About the Site
2028
46K
1 of 5
Featured Stories
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future
As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
How This Former Army Officer Helps Deliver Cancer Treatments to Patients
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
What's next in Neuroscience drug discovery
A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
